株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バイオマーカーの世界市場:癌バイオマーカー、心血管疾患のバイオマーカー、免疫疾患バイオマーカー、感染症バイオマーカー、神経疾患バイオマーカー

The World Market for Biomarkers (Cardiac Markers [cTn, HscTn, Acute CK-MB/BNP, Others], Tumor Markers [PSA, CEA, CA 125, AFP, PSA Rapid, Others], Coagulation Markers [PT/INR, D-dimer], Infectious Disease Markers [by Disease],

発行 Kalorama Information 商品コード 910122
出版日 ページ情報 英文 266 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.55円で換算しております。
Back to Top
バイオマーカーの世界市場:癌バイオマーカー、心血管疾患のバイオマーカー、免疫疾患バイオマーカー、感染症バイオマーカー、神経疾患バイオマーカー The World Market for Biomarkers (Cardiac Markers [cTn, HscTn, Acute CK-MB/BNP, Others], Tumor Markers [PSA, CEA, CA 125, AFP, PSA Rapid, Others], Coagulation Markers [PT/INR, D-dimer], Infectious Disease Markers [by Disease],
出版日: 2019年07月23日 ページ情報: 英文 266 Pages
概要

当レポートでは、世界のバイオマーカー市場について調査し、市場の概要、主な技術、アプリケーション別の分析と予測、市場成長への影響要因、および主要企業のプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 イントロダクション

第3章 バイオマーカーの特定 & 分析に使用される主な技術

  • 概要
  • 免疫測定
  • 免疫組織染色 (IHC)
  • フローケミストリー
  • in situ ハイブリダイゼーション
  • 核酸増幅検査技術
  • ゲノム薬理学
  • 遺伝子シグネチャー
  • マイクロアレイ
  • シーケンシング技術
  • 質量分析
  • 非侵襲出生前検査
  • リキッドバイオプシー
  • デジタルパソロジー・イメージサイトメトリー
  • 情報技術

第4章 癌バイオマーカー

  • 概要
  • 癌のリスク評価
  • 癌スクリーニング
  • 癌の診断・モニタリング
  • 予後予測
  • 個別化医療/プレシジョン検査

第5章 心血管疾患のバイオマーカー

  • 概要
  • 急性心筋梗塞・急性冠症候群バイオマーカー
  • 心不全バイオマーカー
  • 脂質疾患バイオマーカー

第6章 免疫疾患バイオマーカー

  • 概要
  • 自己免疫疾患バイオマーカー
  • 炎症性疾患バイオマーカー
  • その他の免疫関連疾患バイオマーカー

第7章 感染症バイオマーカー

  • 概要
  • 感染症バイオマーカー
  • 抗生物質耐性バイオマーカー
  • 敗血症バイオマーカー

第8章 神経疾患バイオマーカー

  • 概要
  • アルツハイマー病バイオマーカー
  • その他の神経疾患バイオマーカー

第9章 世界のバイオマーカー市場予測

  • 概要
  • バイオマーカー市場全体
  • バイオマーカー市場:アプリケーション別
  • バイオマーカー市場の地域分布
  • 臨床診断バイオマーカー市場:疾患別

第10章 バイオマテリアル市場の分析

  • 概要
  • 市場成長の促進要因・抑制要因

第11章 企業プロファイル

  • 20/20 GENESYSTEMS, INC.
  • ABACUS DIAGNOSTICA OY
  • ABBOTT LABORATORIES
  • ACT GENOMICS CO., LTD
  • ADAPTIVE BIOTECHNOLOGIES CORP.
  • ADMERA HEALTH
  • AGENA BIOSCIENCE INC
  • AGENDIA NV
  • AGILENT TECHNOLOGIES, INC.
  • ALPCO
  • AMBRY GENETICS CORP
  • ATHENA DIAGNOSTICS, INC. /QUEST
  • BANYAN BIOMARKERS, INC.
  • BECKMAN COULTER, INC./DANAHER CORP.
  • BECTON, DICKINSON AND COMPANY
  • BIOFIRE DIAGNOSTICS, LLC/BIOMERIEUX
  • BIOHIT OYJ
  • BIOMERIEUX SA
  • BIO-RAD LABORATORIES, INC
  • CANCER GENETICS, INC
  • CARIS LIFE SCIENCES
  • CEPHEID/DANAHER CORP.
  • CURETIS AG
  • EXACT SCIENCES CORP
  • FOUNDATION MEDICINE, INC.
  • FUJIREBIO, INC
  • GENOMIC HEALTH, INC
  • HOLOGIC, INC
  • ILLUMINA, INC
  • MYRIAD GENETICS
  • NEOGENOMICS
  • ORTHO-CLINICAL DIAGNOSTICS
  • QIAGEN N.V
  • ROCHE
  • SIEMENS HEALTHINEERS
  • SYSMEX CORP
  • THERMO FISHER SCIENTIFIC, INC.
  • VENTANA MEDICAL SYSTEMS, INC./ROCHE
  • ZEUS SCIENTIFIC, INC
目次
Product Code: 19-044

Biomarkers are biological or biochemical molecules, genetic changes, or other characteristics that can be measured; they indicate or predict a condition, risk, or likely biological response. Biomarkers can be used for a range of diagnostic applications including predicting disease risk, diagnosis, predicting prognosis, identifying appropriate therapy for an individual, monitoring disease or for return of a disease, and other applications. ‘The World Market for Biomarkers’ estimates the world markets for biomarkers and biomarker tests from 2014 to 2024, with 2019 as the base year, providing global biomarker market forecasts for the total biomarker market, the market by application (clinical diagnostic biomarker market, research biomarker market), and the market by geographical distribution:

  • Total Global Biomarker Market by Application, 2014 - 2024, in $Millions (Clinical Diagnostic, Research, Total)
  • Biomarker Market Segments by Application, 2014, 2019, 2024, by Share (%) (Clinical Diagnostic, Research)
  • Total Global Biomarker Market by Region 2014 - 2024, in $Millions (North America, European Union, Japan, China, India, ROW, Total)
  • Global Market Segments by Region, 2014, 2019, 2024, by Share (%) (North America, European Union, Japan, China, India, ROW)

Clinical Diagnostic Biomarker Market by Disease

In 2019, growth in the total global market for clinical diagnostic markers has been strong, with strong expansion expected to continue. The report discusses how this growth will be fueled by an aging population that is more susceptible to disease, the increasing number of targeted therapies being developed and introduced, and the large and growing clinical diagnostic test market. Further, analysis in the report of key segments, such as the infectious disease and cancer segments, shows that growth will occur at different rates. The report provides the following data on segments of the clinical diagnostic biomarker market by disease:

  • Total Global Clinical Diagnostic Biomarker Market, 2014 - 2024, in $Millions (Cancer, Cardiovascular Disease, Immunological Disease, Infectious Disease, Neurological Disease, Other, Total)
  • Clinical Diagnostic Biomarker Market Segments, 2014, 2019, 2024, by Share (Cancer, Cardiovascular Disease, Immunological Disease, Infectious Disease, Neurological Disease, Other)

Cancer Biomarker Market

Cancer immunoassays (tumor markers) detect proteins in the blood, urine, or other body fluids such as sputum, breast nipple aspirate, and semen. The presence of these proteins, or their relative levels, may indicate an abnormal process in the body, such as cancer, and can provide further information if cancer is diagnosed. Doctors use tumor marker tests at various stages in patient care: for diagnosis, treatment monitoring and disease recurrence. The report provides the following cancer biomarker market data:

  • Total Global Clinical Diagnostic Cancer Biomarker Market, 2014 - 2024, in $Millions (Histology/Cytology, Immunoassays, Flow Cytometry, Rapid Tests, Molecular Assays, Total)
  • Clinical Diagnostic Cancer Biomarker Market Segments, 2014, 2019, 2024, by Share (%) (Cancer, Cardiovascular Disease, Immunological Disease, Infectious Disease, Neurological Disease)
  • Total Global Clinical Diagnostic Cancer Biomarker Market by Segment, 2014, 2019, 2024, in $Millions (Histology/Cytology: Immunohistochemistry, In Situ Hybridization; Immunoassays - Tumor Markers: PSA, CEA, CA 125, AFP, Others, Flow Cytometry; Rapid Tests: Fecal Occult Blood, PSA, NMP22, Others; Molecular Assays; Total)

Infectious Disease Biomarker Market

The largest disease segment at this time is infectious diseases. This market includes tests to detect antigens or nucleic acid (DNA or RNA) sequences from microbes, and also markers of the body's response to the infection, such as antibodies produced against a specific pathogen that has infected a person. These are important biomarkers to determine if a person is, or has been, infected. These biomarkers can also sometimes be used to demonstrate the efficacy of treatment. For bacterial infections, antibiotic resistance genes are also important biomarkers to predict which antibiotics are not likely to be effective for treatment of a bacterial infection. The report provides the following infectious disease biomarker market data:

  • Total Global Clinical Diagnostic Infectious Disease Biomarker Market, 2014 - 2024, in $Millions (Cardiac Markers, Cholesterol/Lipids, Coagulation, Total)
  • Growth of Global Clinical Diagnostic Infectious Disease Biomarker Market, 2014 - 2024, in $Millions (Laboratory Immunoassays, Rapid Immunoassays, Molecular Assays)
  • Clinical Diagnostic Infectious Disease Biomarker Market Segments, 2014, 2019, 2024, by Share (%) (Laboratory Immunoassays, Rapid Immunoassays, Molecular Assays)
  • Total Global Clinical Diagnostic Infectious Disease Biomarker Market by Segment, 2014, 2019, 2024, in $Millions (Laboratory Immunoassays [Hepatitis; HIV; STDs including chlamydia, gonorrhea and syphilis; TORCH; Respiratory; Sepsis including sepsis markers, C. difficile, MRSA, other AMR/HAI tests; Parasitology; Mycology; Others including EBV, Chagas, dengue, malaria, Lyme disease, others], Rapid Immunoassays [Influenza; HIV; Malaria; Hepatitis; STDs including chlamydia and syphilis; C. difficile; E. coli; Strep A; H. pylori; Others including rapid tests for TB, Dengue, Chagas, vaginitis, Group B Strep and others], Molecular Assays [HAIs; HIV; Hepatitis; Chlamydia/Gonorrhea (CT/NG); HPV; Respiratory; Mycobacteria/TB; Others], Total)

Cardiovascular Disease Biomarker Market

Cardiac biomarkers are substances that are released into the bloodstream when the heart is damaged or stressed. As discussed in the report, cardiovascular disease includes all diseases or disorder of the heart and the vascular system of the body. Many different biomarkers have been identified to help physicians diagnose disease, identify individuals at increased risk of disease, and to monitor certain conditions. ‘The World Market for Biomarkers’ provides the following information on the global diagnostic market for cardiovascular disease biomarkers:

  • Total Global Clinical Diagnostic Cardiovascular Disease Biomarker Market, 2014 - 2024, in $Millions (Cardiac Markers, Cholesterol/Lipids, Coagulation, Total)
  • Clinical Diagnostic Cardiovascular Disease Biomarker Market Segments, 2014, 2019, 2024, by Share (%) (Cardiac Markers, Cholesterol/Lipids, Coagulation)
  • Total Global Clinical Diagnostic Cardiovascular Disease Biomarker Market by Segment, 2014, 2019, 2024, in $Millions (Cardiac Markers [Acute Condition Cardiac Markers: CK-MB, myoglobin, brain natriuretic peptide (BNP); cTn; HscTn; Other cardiac markers: proBNP, hsCRP, homocysteine, others], Cholesterol/Lipids, Coagulation [PT/INR-lab, D-dimer, Molecular (Thrombophilia SNPs), POC], Total)

Immunological Disease Biomarker Market

There are many different diseases that involve an abnormal immune response, as discussed in the report. Two immunological disease categories for which diagnostic testing is commonly performed are autoimmune disease and allergy. More than 80 different autoimmune related diseases have been identified. In addition, individuals can develop an allergic response to a wide array of allergens. As a result, these diagnostic markets include a wide range of different biomarkers that can be tested. The report provides the following information on the sales of biomarkers related to immunological disease:

  • Total Global Clinical Diagnostic Immunological Disease Biomarker Market, 2014 - 2024, in $Millions (Autoimmune Disease, Allergy, Total)
  • Clinical Diagnostic Immunological Disease Biomarker Market Segments, 2014, 2019, 2024, by Share (%) (Autoimmune Disease, Allergy)

Neurological Disease Biomarker Market

Neurological diseases are those that affect the central nervous system (brain and spinal cord) and the peripheral nervous system. This group encompasses many age-related diseases such as dementia, neurodegenerative diseases, inherited neurodevelopmental disorders, as well as autoimmune diseases such as multiple sclerosis, diabetic neuropathy, stroke, and many others. Because they are systemic, distinct, complex and generally not as widespread as the illnesses discussed elsewhere in this report, biomarker development in this area has been slower. However, the aging of the population and rapid increase of severe and costly diseases such as Alzheimer's disease has made this area a priority for a rising number of research groups. As such, it is a fast growing biomarker segment of which the report notes total global sales:

  • Total Global Clinical Diagnostic Neurological Disease Biomarker Market, 2014 - 2024, in $Millions (Autoimmune Disease, Allergy, Total)
  • Clinical Diagnostic Neurological Disease Biomarker Market Segments, 2014, 2019, 2024, by Share (%) (Alzheimer's Disease, Other Neurological Disorders)

Other Diseases

The “other” segment includes many different types of biomarkers used in diagnostic applications such as bone diseases, renal disease, transplantation, other endocrine diseases, and other varied disease indications. As discussed in the report, a broad definition of biomarkers is used has been used in this report. Biomarkers in this report include molecules or other characteristics that can be measured, and are indicators of a health, risk of disease, disease or other condition, prognosis, response to therapy, or other biological effect. This definition includes biomarkers that are used in drug development as surrogates, markers of drug safety, or other applications. Traditionally, biomarkers have been discussed and evaluated as single molecules or characteristics, and many tests are available for individual biomarkers. ‘The World Market for Biomarkers’ provides the following information on the sales of biomarkers related to the following segments: general clinical chemistry, fertility/pregnancy, thyroid, diabetes/Hb1Ac, chromosome analysis & inherited disease, and other:

  • Total Global Clinical Diagnostic Other Biomarker Market, 2014 - 2024, in $Millions (General Clinical Chemistry, Fertility/Pregnancy, Thyroid, Diabetes/Hb1Ac, Chromosome Analysis & Inherited Disease, Other, Total)
  • Clinical Diagnostic Other Biomarker Market Segments, 2014, 2019, 2024, by Share (%)(General Clinical Chemistry, Fertility/Pregnancy, Thyroid, Diabetes/Hb1Ac, Chromosome Analysis & Inherited Disease, Other)

C-Reactive Protein (CRP)

C-Reactive Protein (CRP) is an important biomarker for several diseases. Due to the high and rising interest in CRP tests, a breakout of estimated sales is provided:

  • Total Global CRP Biomarker Market, 2014 - 2024, in $Millions

Biomarker Market Drivers and Restraints

For this report, the market for biomarkers focuses on applications of biomarkers. This includes both research and diagnostic applications of biomarkers. The potential market for biomarkers being evaluated as potential drug targets is not included in this market analysis, as that therapeutic market would be determined by the potential market for new therapies targeting the biomarker drug target.

The report examines biomarker market drivers and restraints. As in other markets, a variety of drivers and restraints exert influences to varying degrees. Some of these drivers and restraints operate at a macro level, affecting the entire industry, while others mainly affect certain segments, companies, geographies, or other select situations. The market for a biomarker that is developed and commercialized for diagnostic applications is driven by the market and need for diagnostic assays that detect that biomarker.

Key Technologies Used to Identify & Analyze Biomarkers

Many different technologies have been developed and are used in biomarker discovery, and also for detection and analysis of known biomarkers. These include traditional technologies, some of which have been used for decades. In addition, many new technologies developed for other applications are now being applied in this field. These include mass spectrometry and next generation DNA sequencing. Many tests performed using newer technologies are currently being done primarily as laboratory developed tests (LDTs) or by organizations performing clinical tests for pharmaceutical companies developing new drugs; however, some companies plan to eventually develop IVD test kits based on their laboratory assays. Selected examples of companies using these various technologies are discussed in this report, including key players in the market:

  • Selected Companies Using Immunoassays for Detection and Analysis of Biomarkers, 2019
  • Selected Companies with Immunohistochemistry Tests for Detection of Biomarkers, 2019
  • Selected Companies Using In Situ Hybridization for Detection and Analysis of Biomarkers, 2019
  • Selected Companies Using PCR or Other Nucleic Acid Amplification-Based Technologies for Biomarker Assays, 2019
  • Selected Companies Analyzing Gene Signatures, 2019
  • Selected Companies Using Microarrays to Detect and Analyze Biomarkers, 2019
  • Selected Diagnostics Companies and Clinical Laboratories with Sequencing-Based Biomarkers, 2019
  • Selected Companies Using Mass Spectrometry, 2019

Competition in the Market

‘The World Market for Biomarkers’ includes profiles of companies active in the discovery and/or commercialization of biomarkers. This includes companies commercializing in vitro diagnostic tests for detection and analysis of biomarkers, selected diagnostic companies commercializing diagnostic tests in their own CLIA certified laboratories for detection and analysis of biomarkers, and selected other players. The report's focus is on companies with commercialized products and/or very advanced development programs. The diagnostics market is a highly competitive market, and there are many additional diagnostic companies that offer tests based on biomarkers discussed in this report.

Companies profiled in the report range from large, multinational companies to smaller companies in or entering this market, including the following:

  • 20/20 GeneSystems, Inc.
  • Abacus Diagnostica Oy
  • Abbott Laboratories
  • Act Genomics Co., Ltd.
  • Adaptive Biotechnologies Corp.
  • Admera Health
  • Agena Bioscience Inc.
  • Agendia NV
  • Agilent Technologies, Inc.
  • ALPCO
  • Ambry Genetics Corp.
  • Athena Diagnostics, Inc. /Quest
  • Banyan Biomarkers, Inc.
  • Beckman Coulter, Inc./Danaher Corp.
  • Becton, Dickinson and Company
  • BioFire Diagnostics, LLC/BioMerieux
  • Biohit Oyj
  • bioMérieux SA
  • Bio-Rad Laboratories, Inc.
  • Cancer Genetics, Inc.
  • Caris Life Sciences
  • Cepheid/Danaher Corp.
  • Curetis AG
  • Exact Sciences Corp.
  • Foundation Medicine, Inc.
  • Fujirebio, Inc.
  • Genomic Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Myriad Genetics
  • NeoGenomics
  • Ortho-Clinical Diagnostics
  • Qiagen N.V.
  • Roche
  • Siemens Healthineers
  • Sysmex Corp.
  • Thermo Fisher Scientific, Inc.
  • Ventana Medical Systems, Inc./Roche
  • Zeus Scientific, Inc.

Table of Contents

CHAPTER 1: EXECUTIVE SUMMARY

  • OVERVIEW
  • SCOPE AND METHODOLOGY
  • MARKET SUMMARY
    • Exhibit 1-1: Total Global Biomarker Market, 2014 - 2024, in $Millions
    • Exhibit 1-2: Growth of Total Global Biomarker Market, 2014 - 2024, in $Millions

CHAPTER 2: INTRODUCTION

  • OVERVIEW
    • What Are Biomarkers?
    • Why Biomarkers Are Important
    • Biomarker Validation
      • Exhibit 2-1: FDA-Qualified Biomarkers, 2019

CHAPTER 3: KEY TECHNOLOGIES USED TO IDENTIFY & ANALYZE BIOMARKERS

  • OVERVIEW
  • IMMUNOASSAYS
    • Key Players
      • Exhibit 3-1: Selected Companies Using Immunoassays for Detection and Analysis of Biomarkers, 2019
  • IMMUNOHISTOCHEMISTRY (IHC)
    • Key Players
      • Exhibit 3-2: Selected Companies with Immunohistochemistry Tests for Detection of Biomarkers, 2019
  • FLOW CYTOMETRY
    • Key Players
  • IN SITU HYBRIDIZATION
    • Key Players
      • Exhibit 3-3: Selected Companies Using In Situ Hybridization for Detection and Analysis of Biomarkers, 2019
  • NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
    • Key Players
      • Exhibit 3-4: Selected Companies Using PCR or Other Nucleic Acid Amplification-Based Technologies for Biomarker Assays, 2019
  • PHARMACOGENOMICS
    • Exhibit 3-5: Pharmacogenomic Biomarkers in Drug Labeling, 2019
  • GENE SIGNATURES
    • Key Players
      • Exhibit 3-6: Selected Companies Analyzing Gene Signatures, 2019
  • MICROARRAYS
    • Key Players
    • Protein Microarrays
      • Exhibit 3-7: Selected Companies Using Microarrays to Detect and Analyze Biomarkers, 2019
    • DNA Microarrays
    • Chromosomal Microarrays
    • Tissue Microarrays
  • SEQUENCING TECHNOLOGIES
    • Key Players
      • Exhibit 3-8: Selected Diagnostics Companies and Clinical Laboratories with Sequencing-Based Biomarkers, 2019
    • Sanger Sequencing
    • Early Next Generation Sequencing Technologies
    • Sequencing by Synthesis (SBS)
    • Supported Oligonucleotide Ligation and Detection (SOLiD)
    • Ion Torrent Sequencing
  • MASS SPECTROMETRY
    • Research and Clinical Applications of Mass Spectrometry
    • Key Players
      • Exhibit 3-9: Selected Companies Using Mass Spectrometry, 2019
  • NON-INVASIVE PRENATAL TESTING
  • LIQUID BIOPSIES - CIRCULATING TUMOR CELLS AND CIRCULATING TUMOR DNA (CELL FREE DNA)
  • DIGITAL PATHOLOGY AND IMAGE CYTOMETRY
  • INFORMATION TECHNOLOGY

CHAPTER 4: CANCER BIOMARKERS

  • OVERVIEW
    • Exhibit 4-1: Widely Used Tumor Markers, 2019
  • ASSESSING RISK OF CANCER
    • Key Players
      • Exhibit 4-2: Selected Biomarkers and Biomarker Panels to Assess Risk of Cancer and Companies Marketing These Biomarkers, 2019
  • CANCER SCREENING
    • Key Players
      • Exhibit 4-3: Selected Biomarkers and Biomarker Panels for Cancer Screening and Companies Marketing These Biomarkers, 2019
  • DIAGNOSIS AND MONITORING OF CANCER
    • Key Players
      • Exhibit 4-4: Selected Biomarkers and Biomarker Panels for Diagnosis and/or Monitoring of Cancer and Companies Marketing These Biomarkers, 2019
  • PREDICTING PROGNOSIS
    • Key Players
  • PERSONALIZED MEDICINE/PRECISION TESTING
    • Key Players
      • Exhibit 4-5: Selected FDA Cleared/Approved Companion Diagnostic Tests and Companies Marketing These Biomarkers, 2019

CHAPTER 5: CARDIOVASCULAR DISEASE BIOMARKERS

  • OVERVIEW
  • ACUTE MYOCARDIAL INFARCTION AND ACUTE CORONARY SYNDROME BIOMARKERS
    • Key Players
  • HEART FAILURE BIOMARKERS
    • Exhibit 5-1: Selected Biomarkers and Biomarker Panels for Cardiovascular Disease and Companies Marketing These Biomarkers, 2019
  • LIPID DISORDER BIOMARKERS
    • Key Players
      • Exhibit 5-2: Selected Lipid Biomarkers and Companies Marketing These Biomarkers, 2019

CHAPTER 6: IMMUNOLOGICAL DISEASE BIOMARKERS

  • OVERVIEW
    • Key Players
  • AUTOIMMUNE DISEASE BIOMARKERS
  • INFLAMMATION/INFLAMMATORY DISEASE BIOMARKERS
  • OTHER IMMUNE-RELATED DISEASE BIOMARKERS
    • Exhibit 6-1: Selected Biomarkers for Immunological Disorders and Companies Marketing These Biomarkers, 2019

CHAPTER 7: INFECTIOUS DISEASE BIOMARKERS

  • OVERVIEW
  • INFECTIOUS DISEASE BIOMARKERS
    • Key Players
      • Exhibit 7-1: Selected Biomarkers for Infectious Disease and Companies Marketing These Biomarkers, 2019
  • ANTIBIOTIC RESISTANCE BIOMARKERS
    • Key Players
      • Exhibit 7-2: Selected Biomarkers and Other Tests for Antibiotic Resistance and Companies Marketing These Biomarkers, 2019
  • SEPSIS BIOMARKERS
    • Key Players
      • Exhibit 7-3: Selected Biomarkers for Sepsis and Companies Marketing These Biomarkers, 2019

CHAPTER 8: NEUROLOGICAL DISEASE BIOMARKERS

  • OVERVIEW
    • Key Players
  • ALZHEIMER'S DISEASE BIOMARKERS
  • OTHER NEUROLOGICAL DISORDER BIOMARKERS
    • Exhibit 8-1: Selected Biomarkers for Neurological Disorders and Companies Marketing These Biomarkers, 2019

CHAPTER 9: GLOBAL BIOMARKER MARKET FORECASTS

  • OVERVIEW
  • TOTAL BIOMARKER MARKET
  • BIOMARKER MARKET BY APPLICATION
    • Clinical Diagnostic Biomarker Market
    • Research Biomarker Market
      • Exhibit 9-1: Total Global Biomarker Market by Application, 2014 - 2024, in $Millions (Clinical Diagnostic, Research, Total)
      • Exhibit 9-2: Growth of Global Biomarker Market by Application, 2014 - 2024, in $Millions (Clinical Diagnostic, Research)
      • Exhibit 9-3: Biomarker Market Segments by Application, 2014, 2019, 2024, by Share (%) (Clinical Diagnostic, Research)
  • BIOMARKER MARKET GEOGRAPHICAL DISTRIBUTION
    • Exhibit 9-4: Total Global Biomarker Market by Region 2014 - 2024, in $Millions (North America, European Union, Japan, China, India, ROW, Total)
    • Exhibit 9-5: Growth of Global Biomarker Market by Region, 2014 - 2024, in $Millions (North America, European Union, Japan, China, India, ROW)
    • Exhibit 9-6: Global Market Segments by Region, 2014, 2019, 2024, by Share (%) (North America, European Union, Japan, China, India, ROW)
  • CLINICAL DIAGNOSTIC BIOMARKER MARKET BY DISEASE
    • Exhibit 9-7: Total Global Clinical Diagnostic Biomarker Market, 2014 - 2024, in $Millions (Cancer, Cardiovascular Disease, Immunological Disease, Infectious Disease, Neurological Disease, Other, Total)
    • Exhibit 9-8: Growth of Total Global Clinical Diagnostic Biomarker Market, 2014 - 2024, in $Millions (Cancer, Cardiovascular Disease, Immunological Disease, Infectious Disease, Neurological Disease, Other)
    • Exhibit 9-9: Clinical Diagnostic Biomarker Market Segments, 2014, 2019, 2024, by Share (Cancer, Cardiovascular Disease, Immunological Disease, Infectious Disease, Neurological Disease, Other)
  • Cancer Biomarker Market
    • Exhibit 9-10: Total Global Clinical Diagnostic Cancer Biomarker Market, 2014 - 2024, in $Millions (Histology/Cytology, Immunoassays, Flow Cytometry, Rapid Tests, Molecular Assays, Total)
    • Exhibit 9-11: Growth of Global Clinical Diagnostic Cancer Biomarker Market, 2014 - 2024, in $Millions (Cancer, Cardiovascular Disease, Immunological Disease, Infectious Disease, Neurological Disease)
    • Exhibit 9-12: Clinical Diagnostic Cancer Biomarker Market Segments, 2014, 2019, 2024, by Share (%) (Cancer, Cardiovascular Disease, Immunological Disease, Infectious Disease, Neurological Disease)
    • Exhibit 9-13: Total Global Clinical Diagnostic Cancer Biomarker Market by Segment, 2014, 2019, 2024, in $Millions (Histology/Cytology: Immunohistochemistry, In Situ Hybridization; Immunoassays - Tumor Markers: PSA, CEA, CA 125, AFP, Others, Flow Cytometry; Rapid Tests: Fecal Occult Blood, PSA, NMP22, Others; Molecular Assays; Total)
  • Cardiovascular Disease Biomarker Market
    • Exhibit 9-14: Total Global Clinical Diagnostic Cardiovascular Disease Biomarker Market, 2014 - 2024, in $Millions (Cardiac Markers, Cholesterol/Lipids, Coagulation, Total)
    • Exhibit 9-15: Growth of Global Clinical Diagnostic Cardiovascular Disease Biomarker Market, 2014 - 2024, in $Millions (Cardiac Markers, Cholesterol/Lipids, Coagulation)
    • Exhibit 9-16: Clinical Diagnostic Cardiovascular Disease Biomarker Market Segments, 2014, 2019, 2024, by Share (%) (Cardiac Markers, Cholesterol/Lipids, Coagulation)
    • Exhibit 9-17: Total Global Clinical Diagnostic Cardiovascular Disease Biomarker Market by Segment, 2014, 2019, 2024, in $Millions (Cardiac Markers [Acute Condition Cardiac Markers: CK-MB, myoglobin, brain natriuretic peptide (BNP); cTn; HscTn; Other cardiac markers: proBNP, hsCRP, homocysteine, others], Cholesterol/Lipids, Coagulation [PT/INR-lab, D-dimer, Molecular (Thrombophilia SNPs), POC], Total)
  • Immunological Disease Biomarker Market
    • Exhibit 9-18: Total Global Clinical Diagnostic Immunological Disease Biomarker Market, 2014 - 2024, in $Millions (Autoimmune Disease, Allergy, Total)
    • Exhibit 9-19: Growth of Global Clinical Diagnostic Immunological Disease Biomarker Market, 2014 - 2024, in $Millions (Autoimmune Disease, Allergy)
    • Exhibit 9-20: Clinical Diagnostic Immunological Disease Biomarker Market Segments, 2014, 2019, 2024, by Share (%) (Autoimmune Disease, Allergy)
  • Infectious Disease Biomarker Market
    • Exhibit 9-21: Total Global Clinical Diagnostic Infectious Disease Biomarker Market, 2014 - 2024, in $Millions (Cardiac Markers, Cholesterol/Lipids, Coagulation, Total)
    • Exhibit 9-22: Growth of Global Clinical Diagnostic Infectious Disease Biomarker Market, 2014 - 2024, in $Millions (Laboratory Immunoassays, Rapid Immunoassays, Molecular Assays)
    • Exhibit 9-23: Clinical Diagnostic Infectious Disease Biomarker Market Segments, 2014, 2019, 2024, by Share (%) (Laboratory Immunoassays, Rapid Immunoassays, Molecular Assays)
    • Exhibit 9-24: Total Global Clinical Diagnostic Infectious Disease Biomarker Market by Segment, 2014, 2019, 2024, in $Millions (Laboratory Immunoassays [Hepatitis; HIV; STDs including chlamydia, gonorrhea and syphilis; TORCH; Respiratory; Sepsis including sepsis markers, C. difficile, MRSA, other AMR/HAI tests; Parasitology; Mycology; Others including EBV, Chagas, dengue, malaria, Lyme disease, others], Rapid Immunoassays [Influenza; HIV; Malaria; Hepatitis; STDs including chlamydia and syphilis; C. difficile; E. coli; Strep A; H. pylori; Others including rapid tests for TB, Dengue, Chagas, vaginitis, Group B Strep and others], Molecular Assays [HAIs; HIV; Hepatitis; Chlamydia/Gonorrhea (CT/NG); HPV; Respiratory; Mycobacteria/TB; Others], Total)
  • Neurological Disease Biomarker Market
    • Exhibit 9-25: Total Global Clinical Diagnostic Neurological Disease Biomarker Market, 2014 - 2024, in $Millions (Autoimmune Disease, Allergy, Total)
    • Exhibit 9-26: Growth of Global Clinical Diagnostic Neurological Disease Biomarker Market, 2014 - 2024, in $Millions (Alzheimer's Disease, Other Neurological Disorders)
    • Exhibit 9-27: Clinical Diagnostic Neurological Disease Biomarker Market Segments, 2014, 2019, 2024, by Share (%) (Alzheimer's Disease, Other Neurological Disorders)
  • Other Biomarker Markets
    • Exhibit 9-28: Total Global Clinical Diagnostic Other Biomarker Market, 2014 - 2024, in $Millions (General Clinical Chemistry, Fertility/Pregnancy, Thyroid, Diabetes/Hb1Ac, Chromosome Analysis & Inherited Disease, Other, Total)
    • Exhibit 9-29: Growth of Global Clinical Diagnostic Other Biomarker Market, 2014 - 2024, in $Millions (General Clinical Chemistry, Fertility/Pregnancy, Thyroid, Diabetes/Hb1Ac, Chromosome Analysis & Inherited Disease, Other)
    • Exhibit 9-30: Clinical Diagnostic Other Biomarker Market Segments, 2014, 2019, 2024, by Share (%)(General Clinical Chemistry, Fertility/Pregnancy, Thyroid, Diabetes/Hb1Ac, Chromosome Analysis & Inherited Disease, Other)
  • C-Reactive Protein (CRP)
    • Exhibit 9-31: Total Global CRP Biomarker Market, 2014 - 2024, in $Millions
    • Exhibit 9-32: Growth of Global CRP Biomarker Market, 2014 - 2024, in $Millions

CHAPTER 10: BIOMARKER MARKET ANALYSIS

  • OVERVIEW
  • MARKET DRIVERS AND RESTRAINTS
    • Market Drivers
    • Market Restraints

CHAPTER 11: COMPANY PROFILES

  • Exhibit 11-1: Selected Players in the Global Biomarker Market, 2019
  • 20/20 GENESYSTEMS, INC.
  • ABACUS DIAGNOSTICA OY
  • ABBOTT LABORATORIES
  • ACT GENOMICS CO., LTD
  • ADAPTIVE BIOTECHNOLOGIES CORP.
  • ADMERA HEALTH
  • AGENA BIOSCIENCE INC
  • AGENDIA NV
  • AGILENT TECHNOLOGIES, INC.
  • ALPCO
  • AMBRY GENETICS CORP
  • ATHENA DIAGNOSTICS, INC. /QUEST
  • BANYAN BIOMARKERS, INC.
  • BECKMAN COULTER, INC./DANAHER CORP.
  • BECTON, DICKINSON AND COMPANY
  • BIOFIRE DIAGNOSTICS, LLC/BIOMERIEUX
  • BIOHIT OYJ
  • BIOMÉRIEUX SA
  • BIO-RAD LABORATORIES, INC
  • CANCER GENETICS, INC
  • CARIS LIFE SCIENCES
  • CEPHEID/DANAHER CORP.
  • CURETIS AG
  • EXACT SCIENCES CORP
  • FOUNDATION MEDICINE, INC.
  • FUJIREBIO, INC
  • GENOMIC HEALTH, INC
  • HOLOGIC, INC
  • ILLUMINA, INC
  • MYRIAD GENETICS
  • NEOGENOMICS
  • ORTHO-CLINICAL DIAGNOSTICS
  • QIAGEN N.V
  • ROCHE
  • SIEMENS HEALTHINEERS
  • SYSMEX CORP
  • THERMO FISHER SCIENTIFIC, INC.
  • VENTANA MEDICAL SYSTEMS, INC./ROCHE
  • ZEUS SCIENTIFIC, INC
Back to Top